Contact Us
Home Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

News Release

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

May 13, 2013
PDF Version

DUBLIN, May 13, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in three upcoming investor events. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. The events, presentation times and speakers include:

  • UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 9:30 a.m. EDT/2:30 p.m. IST. Kathryn E. Falberg, executive vice president and chief financial officer, will provide a business update.
  • Jefferies 2013 Global Healthcare Conference in New York, NY on Tuesday, June 4, 2013 at 8:30 a.m. EDT/1:30 p.m. IST. Bruce C. Cozadd, chairman and chief executive officer, will provide a business update.
  • Lazard Capital Markets Conference Call at the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS) in Baltimore, MD on Wednesday, June 5, 2013 at 12:30 p.m. EDT/5:30 p.m. IST. Company management will discuss data being presented, including findings from the Burden of Narcolepsy Disease (BOND) study, and other business matters.

An archived version of each audio webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion and FazaClo® (clozapine, USP) HD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals plc

Investor Contact, Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, + 353 1 634 7887, U.S., + 1 650 496 2717